BioNTech acquires T cell therapy-focused Neon for $67m
BioNTech has acquired Neon Therapeutics in an all stock transaction valued at $2.18...
Focus:
-
![]()
Merck closes $2.7bn acquisition of biopharmaceutical firm ArQule
-
![MorphoSys Incyte B cell deal]()
MorphoSys and Incyte sign $900m deal for B-cell malignancies drug
-
![Lilly to acquire Dermira]()
Lilly to acquire Dermira for approximately $1.1bn
-
![Pfizer oncology eFFECTOR]()
Pfizer signs oncology agreement with STR-focused eFFECTOR
-
![]()
Merck collaborates on small molecule inhibitors with Taiho and Astex
-
![AstraZeneca sells Arimidex and Casodex rights]()
AstraZeneca sells Arimidex and Casodex rights for $181m
Most Read
- BioNTech acquires T cell therapy-focused Neon for $67m
- MorphoSys and Incyte sign $900m deal for B-cell malignancies drug
- Pfizer signs oncology agreement with STR-focused eFFECTOR
- Merck collaborates on small molecule inhibitors with Taiho and Astex
- China in 2019: a prime destination for pharma R&D deals
Latest Content
BioNTech acquires T cell therapy-focused Neon for $67m
BioNTech has acquired Neon Therapeutics in an all stock transaction valued at $2.18 per share or approximately $67m. According to the terms of the deal, Neon will be merged with ENDOR Lights, a wholly owned subsidiary of BioNTech.
Merck closes $2.7bn acquisition of biopharmaceutical firm ArQule
Merck (MSD) has completed its previously announced acquisition of US-based biopharmaceutical company ArQule.
MorphoSys and Incyte sign $900m deal for B-cell malignancies drug
Germany-based MorphoSys has announced it has signed a collaboration and license agreement with the US company Incyte to continue the global development and commercialisation of the former’s tafasitamab (MOR208) for B-cell malignancies.
NeuroBo Pharmaceuticals complete Gemphire merger
NeuroBo Pharmaceuticals has completed its previously announced combination with Gemphire Therapeutics.
Lilly to acquire Dermira for approximately $1.1bn
Eli Lilly and Company (Lilly) has signed a definitive agreement to acquire biopharmaceutical firm Dermira for approximately $1.1bn in cash.
Pfizer signs oncology agreement with STR-focused eFFECTOR
San Diego-based eFFECTOR has signed an exclusive worldwide license and collaboration agreement with Pfizer in the oncology field.
Altavant Sciences acquires Onspira Therapeutics
Altavant Sciences has signed a definitive agreement to acquire private drug development firm Onspira Therapeutics.
Almirall signs option agreement to acquire Bioniz Therapeutics
Spanish drugmaker Almirall has signed an option agreement to acquire Bioniz Therapeutics, a clinical-stage biopharmaceutical company in California.
Galen acquires Nordic-based POA Pharma in multi-million pound deal
Northern Ireland-based, globally focused pharmaceutical sales and marketing firm Galen has acquired Swedish-headquartered POA Pharma in a multi-million pound takeover agreement.
Merck collaborates on small molecule inhibitors with Taiho and Astex
Merck has signed an exclusive worldwide research collaboration and licence agreement with two Otsuka Pharmaceutical subsidiaries, Japanese Taiho Pharmaceutical and UK-based Astex Pharmaceuticals.
Latest News
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.
Close
Close
Close
Go Top
